CYPH
Cypherpunk TechnologiesยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About CYPH
Cypherpunk Technologies Inc.
Research and Development of New Cancer Therapies and Digital Asset Treasury Layout Related to Zcash
47 Thorndike Street, Suite B1-1, Cambridge, MA 02141
--
Cypherpunk Technologies Inc., originally established as Dekkun Corporation on January 3, 2011, is a Delaware corporation. On November 13, 2025, the company changed its name to Cypherpunk Technologies Inc. The company is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat cancer patients by inhibiting basic tumor-promoting pathways, targeting cancer-specific cell surface molecules and using the immune system to attack cancer cells. Their strategy is to identify, acquire and develop molecules that will rapidly translate into high-impact treatments that produce long-lasting clinical benefits and improve patient outcomes. Their main clinical stage project is DKN-01, a monoclonal antibody that inhibits dickkopf-associated protein 1 (" DKK1 "). They are currently investigating the application of DKN-01 in patients with esophageal, gastric, gynecological or colorectal cancer in several ongoing clinical trials. Their second clinical stage project is FL -301, a monoclonal antibody against cells expressing Claudin 18.2 on the cell surface. They also have two preclinical antibody programs, FL-302 and FL-501.
Company Financials
EPS
CYPH has released its 2025 Q3 earnings. EPS was reported at -0.08, versus the expected -0.24, beating expectations. The chart below visualizes how CYPH has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
